Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields(University of Pittsburgh), M. Hong Nguyen(University of Pittsburgh), Liang Chen(Rutgers, The State University of New Jersey), Ellen G. Press(University of Pittsburgh), Brian A. Potoski(University of Pittsburgh), Rachel V Marini(University of Pittsburgh Medical Center), Yohei Doi(University of Pittsburgh), Barry N. Kreiswirth(Rutgers, The State University of New Jersey), Cornelius J. Clancy(University of Pittsburgh)
Cited by 484Open Access
Abstract
ABSTRACT There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success ( P = 0.006) and survival ( P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity ( P = 0.002).
Related Papers
No related papers found
Powered by citation graph analysis